Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.

The goal of this observational study is to use endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) to investigate the intratumoral microbiome profile in patients with pancreatic ductal adenocarcinoma (PDAC) and to evaluate its potential impact on tumor diagnosis and prognosis. PDAC is the most common and lethal type of pancreatic cancer, accounting for over 85% of all pancreatic cancer cases. Given that most patients are diagnosed at an advanced stage when surgery is no longer an option, EUS-FNB serves as a crucial and minimally invasive method for accessing and analyzing the microbiome within the tumor.
The main questions this study aims to answer are:
Can EUS-FNB reliably and accurately detect the microbiome within PDAC tumors?
Researchers will analyze tissue samples obtained through EUS-FNB to confirm its ability to accurately capture the diversity and composition of the tumor microbiome.
Are there specific microbes or metabolites within the PDAC tumor microbiome that are linked to patient prognosis or response to chemotherapy?
The study will screen for and identify key microbial species or metabolites associated with treatment outcomes and patient survival in PDAC.
To ensure the reliability of the EUS-FNB results, researchers will systematically compare microbiome data obtained from EUS-FNB samples with those from surgical biopsies of pancreatic cancer tissue. This comparison will help validate the consistency and accuracy of the two methods in identifying the microbiome diversity and composition, confirming the clinical and research utility of EUS-FNB.
Participant Requirements:
Participants will be patients diagnosed with PDAC who require EUS-FNB as part of their clinical assessment and treatment pathway.
During the EUS-FNB procedure, researchers will use the remaining tissue after rapid on-site evaluation (ROSE) to conduct microbiome sequencing, ensuring sample quality.
All participants will provide informed consent, allowing the use of leftover tissue for microbiome analysis, and their privacy will be strictly protected throughout the study.
Study Procedures:
Participants will undergo a standard EUS-FNB procedure as part of their routine clinical care, with no additional procedures required for the study.
Researchers will compare the microbiome characteristics from EUS-FNB samples with those from surgical biopsy samples to verify consistency.
The study will utilize 2bRAD-M metagenomic sequencing technology, which is cost-effective and suitable for low-biomass, host-contaminated, and degraded microbiome samples. This method generates an accurate species-level taxonomic profile for analysis.
By identifying key microbial components or metabolites linked to patient prognosis or treatment response, this study aims to provide scientific evidence for early detection strategies and effective treatment plans for PDAC patients, potentially bringing significant clinical benefits.

Start Date01 Oct 2024

Sponsor / Collaborator

The Third Xiangya Hospital of Central South University

ChiCTR2400088565 / SuspendedPhase 1IIT

The impact of strict and relaxed red blood cell infusion strategies on chemotherapy related serious adverse reactions in children with acute leukemia - a multicenter crossover design randomized controlled trial

Start Date09 Sep 2024

Sponsor / Collaborator

The Third Xiangya Hospital of Central South University

100 Clinical Results associated with The Third Xiangya Hospital of Central South University

0 Patents (Medical) associated with The Third Xiangya Hospital of Central South University

2,506

Literatures (Medical) associated with The Third Xiangya Hospital of Central South University

31 Dec 2024·International Journal of Hyperthermia

Risk assessment and prediction of occult uterine sarcoma in patients with presumed uterine fibroids before high-intensity focused ultrasound treatment

Article

Author: Zhang, Ying ; Wang, Qian ; He, Min ; Zhu, Xiaogang ; Zhang, Lian ; Lin, Zhenjiang ; Wang, Yangyang

OBJECTIVETo develop a diagnostic model for predicting occult uterine sarcoma in patients with presumed uterine fibroids.MATERIALS AND METHODSWe retrospectively reviewed 41631 patients with presumed uterine fibroids who presented for HIFU treatment in 13 hospitals between November 2008 and October 2023. Of these patients, 27 with occult uterine sarcoma and 54 with uterine fibroids were enrolled. Univariate analysis and multivariate logistics regression analysis were used to determine the independent risk factors for the diagnosis of occult uterine sarcoma. A prediction model was constructed based on the coefficients of the risk factors.RESULTSThe multivariate analysis revealed abnormal vaginal bleeding, ill-defined boundary of tumor, hyperintensity on T2WI, and central unenhanced areas as independent risk factors. A scoring system was created to assess for occult uterine sarcoma risk. The score for abnormal vaginal bleeding was 56. The score for ill-defined lesion boundary was 90. The scores for lesions with hypointensity, isointensity signal/heterogeneous signal intensity, and hyperintensity on T2WI were 0, 42, and 93, respectively. The scores for lesions without enhancement on the mass margin, uniform enhancement of tumor, and no enhancement in the center of tumor were 0, 20, and 100, respectively. Patients with a higher total score implied a higher likelihood of a diagnosis of occult uterine sarcoma than that of patients with a lower score. The established model showed good predictive efficacy.CONCLUSIONSOur results demonstrated that the diagnostic prediction model can be used to evaluate the risk of uterine sarcoma in patients with presumed uterine fibroids.

31 Dec 2024·Cancer Biology & Therapy

METTL14 decreases FTH1 mRNA stability via m6A methylation to promote sorafenib-induced ferroptosis of cervical cancer

Article

Author: He, Sili ; Li, Lijie ; Zeng, Jie ; Wang, Chen ; Yang, Yanfei

Cervical cancer (CC) is a prevalent malignancy among women worldwide. This study was designed to investigate the role of METTL14 in sorafenib-induced ferroptosis in CC. METTL14 expression and m6A methylation were determined in CC tissues, followed by analyzes correlating these factors with clinical features. Subsequently, METTL14 was knocked down in CC cell lines, and the effects on cell proliferation, mitochondrial morphology and ferroptosis were assessed using CCK-8, microscopy, and markers associated with ferroptosis, respectively. The regulatory relationship between METTL14 and FTH1 was verified using qRT-PCR and luciferase reporter assays. The functional significance of this interaction was further investigated both in vitro and in vivo by co-transfecting cells with overexpression vectors or shRNAs targeting METTL14 and FTH1 after sorafenib treatment. METTL14 expression and m6A methylation were significantly reduced in CC tissues, and lower METTL14 expression levels were associated with a poorer CC patients' prognosis. Notably, METTL14 expression increased during sorafenib-induced ferroptosis, and METTL14 knockdown attenuated the ferroptotic response induced by sorafenib in CC cells. FTH1 was identified as a direct target of METTL14, with METTL14 overexpression leading to increased m6A methylation of FTH1 mRNA, resulting in reduced stability and expression of FTH1 in CC. Furthermore, FTH1 overexpression or treatment with LY294002 partially counteracted the promotion of sorafenib-induced ferroptosis by METTL14. In vivo xenograft experiments demonstrated that inhibiting METTL14 reduced the anticancer effects of sorafenib, whereas suppression of FTH1 significantly enhanced sorafenib-induced ferroptosis and increased its anticancer efficacy. METTL14 reduces FTH1 mRNA stability through m6A methylation, thereby enhancing sorafenib-induced ferroptosis, which contributes to suppressing CC progression via the PI3K/Akt signaling pathway.

31 Dec 2024·International Journal of Hyperthermia

Efficacy and influencing factor analysis of high-intensity focused ultrasound therapy for abdominal wall endometriosis: a case series

Article

Author: Cheng, Hui ; Sun, Xin ; Liu, Mengying ; Xue, Min ; Zhu, Xiaogang ; He, Yuyin

OBJECTIVEThe aim of this retrospective study was to investigate the short-term and long-term efficacy of high-intensity focused ultrasound (HIFU) therapy for abdominal wall endometriosis (AWE) and explore its potential influencing factors.MATERIALS AND METHODSA total of 80 patients with AWE who underwent HIFU therapy were retrospectively analyzed. Follow-ups were also conducted to evaluate the changes in lesion size and pain relief. Multivariate logistic regression analysis was applied to investigate factors influencing HIFU therapy for AWE.RESULTSAmong the 80 patients with AWE who received HIFU therapy, the effective rates were 76.3%, 80.5%, and 90.5% after 3, 12 and 24 months of follow-up, respectively. Multivariate logistic regression analysis revealed that the AWE lesion diameter and sonication intensity had statistically significant effects on the 3-month and 12-month efficacy of HIFU therapy for AWE, while age, BMI, disease duration, average sonication power and grey-scale changes did not have statistically significant effects. Four patients with AWE experienced recurrence after HIFU therapy, for a three-year cumulative recurrence rate of 6.3%. Furthermore, ten patients required reintervention after treatment, for a five-year cumulative reintervention rate of 13.9%.CONCLUSIONSThis study further confirmed the safety and effectiveness of HIFU therapy for AWE. Factors such as AWE lesion diameter and sonication intensity have been identified as key influencers affecting the short-term and long-term efficacy of HIFU therapy for AWE. The first two years following HIFU therapy constitute crucial periods for observation, and judiciously extending follow-up intervals during this timeframe is advised.

News (Medical) associated with The Third Xiangya Hospital of Central South University

01 Oct 2024

·www.drugs.com

Weight-Adjusted Waist Index Positively Tied to Overactive Bladder

TUESDAY, Oct. 1, 2024 -- The weight-adjusted waist index (WWI) may be able to predict future incidence of overactive bladder (OAB) in adults, according to a study published online Sept. 3 in Frontiers in Nutrition . Zeng Hui, from the Third Xiangya Hospital at Central South University in Changsha, China, and colleagues used data from the National Health and Nutrition Examination Survey (2009 to 2018; 35,950 individuals) to examine the correlation between WWI and OAB. The researchers found that individuals with a higher WWI had a higher risk for OAB (odds ratio, 1.41). The relationship between WWI and OAB was consistent across various population characteristics. There was a positive nonlinear relationship between WWI and OAB in smoothing curve fitting. The association between WWI and OAB was stronger than with other obesity-related indicators. "In this study, we found a positive relationship between higher WWI levels and an increased risk of OAB," the authors write. "Furthermore, the relationship between WWI and OAB is stronger than the correlation between other obesity markers and OAB, indicating that WWI may serve as a simple anthropometric indicator for predicting OAB." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with The Third Xiangya Hospital of Central South University

100 Translational Medicine associated with The Third Xiangya Hospital of Central South University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CN116617365 ( PDL1 )	Pharyngeal Diseases More	Discovery
DNAzyme targeting EBV-LMP1(Xiangya Hospital of Central South University)	Nasopharyngeal Carcinoma More	Pending
SI-2 ( NLRP3 )	Inflammation More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis